and studies will also need to address the issue of duration of aspirin
therapy needed to achieve clinical benefit. Research into the mechanistic basis of aspirin’s
efficacy in PIK3CA mutated CRCs is eagerly awaited. In an era of targeted therapy that is
increasing health care costs, aspirin is an inexpensive and well tolerated drug that may prove
to be an effective agent to prevent colon cancer recurrence.